JNJ·Healthcare·Dividend Aristocrats
Johnson & Johnson Oncology +1.8%: Pipeline Drives Stock Rally
Can the rapidly expanding Johnson & Johnson Oncology pipeline secure the company's legendary Dividend King status for the next decade?
Pharma
JNJ·Healthcare·Dividend Aristocrats
NVO·Healthcare·Pharma
Novo Nordisk Lawsuit: Shock Clash Over $120B Obesity Market
Will a high-stakes legal battle over deceptive advertising help Novo Nordisk reclaim its crown in the booming obesity market?
LLY·Healthcare·Pharma
Eli Lilly Market Share Booms as LLY Dominates the $100B Obesity Market
Will Eli Lilly's aggressive expansion completely sideline Novo Nordisk in the multi-billion-dollar battle for weight-loss supremacy?
ISRG·Healthcare·Pharma
Intuitive Surgical AI: 18% Revenue Surge Sparks Unexpected Plunge
Can the new Intuitive Surgical AI framework save the stock from its sudden plunge despite stellar quarterly earnings?
NVO·Healthcare·Pharma
Novo Nordisk Lawsuit: $100B Obesity Market Battle Ignites
Will the high-stakes Novo Nordisk lawsuit against Eli Lilly reshape the $100 billion weight-loss market for investors?
ISRG·Healthcare·Pharma
Intuitive Surgical Earnings Rise 19% But Spark Shock Sell-Off
Why did Intuitive Surgical's stellar earnings report trigger a sudden wave of analyst price target cuts?
LLY·Healthcare·Pharma
Eli Lilly Lawsuit: LLY Stock Rallies +2.3% Amid Novo Nordisk Clash
Will Novo Nordisk's aggressive new lawsuit halt Eli Lilly's massive weight-loss market dominance, or is the stock rally unstoppable?
ISRG·Healthcare·Pharma
Intuitive Surgical Earnings Plunge 11% as Growth Hits 4-Year Low
Will the sudden slowdown in robotic surgery adoption permanently derail Intuitive Surgical's premium valuation?
MRK.DE·Healthcare·Pharma
Merck Lipfendra Approval: FDA Clears Breakthrough Pill as Stock Drops -1.75%
Will the revolutionary Merck Lipfendra Approval be enough to offset the looming $32 billion Keytruda patent cliff for investors?
ABT·Healthcare·Dividend Aristocrats
Abbott Laboratories Earnings: Stock Surges 11% on Q2 Beat
Can Abbott Laboratories' upgraded full-year outlook sustain this massive double-digit stock rally, or is the relief surge short-lived?